Actively Recruiting
Immune Biomarkers in Prostate Cancer Patients Treated With Brachytherapy
Led by University of Erlangen-Nürnberg Medical School · Updated on 2025-11-18
200
Participants Needed
3
Research Sites
139 weeks
Total Duration
On this page
Sponsors
U
University of Erlangen-Nürnberg Medical School
Lead Sponsor
B
Bavarian Cancer Research Center (BZKF)
Collaborating Sponsor
AI-Summary
What this Trial Is About
Analysis of peripheral immune cells before, during, and after brachytherapy treatment. Corresponding analysis of tissue samples collected during brachytherapy treatment.
CONDITIONS
Official Title
Immune Biomarkers in Prostate Cancer Patients Treated With Brachytherapy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Primary treatment with I-125 seeds or HDR-BT
- No previous treatment for prostate cancer
- Age �3e�3d 18 years
- HDR- or PDR-BT for salvage treatment
- No radiation therapy within three months before salvage treatment
- Complete documentation on previous prostate cancer treatment
- No history of prostatectomy
- Age �3e�3d 18 years
You will not qualify if you...
- Pre-existent auto-immune disease
- Patients under blood-thinning medication
- Substance abuse
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
Klinik für Strahlentherapie
Augsburg, Bavaria, Germany, 86156
Not Yet Recruiting
2
Strahlenklinik Erlangen
Erlangen, Bavaria, Germany, 91054
Actively Recruiting
3
Klinik und Poliklinik für Strahlentherapie und Radioonkologie
Munich, Bavaria, Germany, 81377
Not Yet Recruiting
Research Team
C
Claudia Schweizer, MD
CONTACT
A
Anna-Jasmina Donaubauer, Dr. rer. nat.
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here